ADC Therapeutics Sees $21 Million In ZYNLONTA Sales And Cash Lasting Into 2029

The lymphoma drugmaker also reported an 88.7% response rate for ZYNLONTA plus glofitamab and previewed five oral talks at December's ASH meeting.

Share
ADC Therapeutics Sees $21 Million In ZYNLONTA Sales And Cash Lasting Into 2029

ADC Therapeutics, which develops cancer drugs that pair a tumor-targeting antibody with a toxin, expects $21 million in third-quarter net sales of its lymphoma drug ZYNLONTA and says its cash should last into 2029 after a restructuring of its financing. The company laid out the preliminary figures in an 8-K filed Wednesday, alongside new trial data headed for the American Society of Hematology meeting.

Sales up, cash down, runway extended

The $21 million estimate for the quarter ended September 30 compares with $16 million a year earlier. For the first nine months, expected sales are $60 million against $51 million. The company attributed the gains primarily to higher sales volume. The figures are preliminary and not yet finalized by management.

Cash and equivalents were $189.2 million at September 30, down from $219 million at the end of the second quarter. The third-quarter spending included $13 million of one-time severance and retention payments. Pro forma cash after the financing steps is $196 million.

That adjusted figure counts about $76 million of net proceeds from the private placement and a $68.5 million partial prepayment of the senior secured term loan, which closed on October 22.

A $86.6 million raise and a loan reset

The restructuring has several separate pieces. The company announced an $86.6 million private placement with Bain Capital Life Sciences as a new investor and Redmile, TCGX and Nantahala Capital among existing ones.

It amended its HealthCare Royalty financing agreement, removing a $150 million change-of-control payment, and cut the exercise price on about 9.8 million warrants from $3.8130 to $0.10.

Separately, the senior secured loan was refinanced to $50 million of principal, due as a single payment in August 2029, with no minimum liquidity requirement. Its revenue covenant is a flat $65 million, versus $70 million in 2026 and up to $94 million in 2029.

Lymphoma data for ASH

The company will present five oral talks at the meeting in New Orleans, December 12 to 15. In the early-stage LOTIS-7 trial of ZYNLONTA plus glofitamab, 97 evaluable patients showed an 88.7% overall response rate and a 75.3% complete response rate as of a June 15 data cutoff. Cytokine release syndrome occurred in 32% of patients, and three deaths were treatment-related adverse events.

A investigator-led marginal zone lymphoma study of 43 evaluable patients showed a 93% response rate and 74.4% complete responses.

The full Phase 3 LOTIS-5 results will also be presented. The trial met its main goal of progression-free survival, 6.14 months versus 4.73 months for chemotherapy, but deaths from adverse events were higher in the ZYNLONTA arm, 13.2% versus 4.6% within the protocol window. The company's forward-looking statements cite serious concerns the FDA raised at a recent pre-submission meeting, and it expects to update its regulatory strategy later.

CEO Ameet Mallik said the LOTIS-7 and marginal zone data support "an expanded role in treating these B-cell malignancies through potential compendia and regulatory pathways."

ADC Therapeutics reports full third-quarter results on Monday, November 9.

Sources

More on ADC Therapeutics

All ADC Therapeutics (ADCT) coverage →